Surgical Menopause (Bilateral Oophorectomy) & POI Hormone Protocol: Protecting Brain, Bone & Heart Under Age 45

01POI, early menopause and surgical menopause: who this playbook is for

Three overlapping groups share the same core problem: losing ovarian estrogen years or decades before the body expects it.

Premature ovarian insufficiency (POI)

Loss of ovarian function before age 40, diagnosed by four or more months of missed or irregular periods and an FSH above 25 IU/L, confirmed on repeat testing when the picture is uncertain. It affects about 1 in 100 women, with some recent estimates higher. Unlike menopause, ovarian function can fluctuate: about 5%–10% of women with POI conceive spontaneously.

Early menopause

Menopause between ages 40 and 45, natural or induced.

Surgical menopause

Removal of both ovaries (bilateral oophorectomy) before natural menopause — for example for endometriosis, ovarian masses, or to reduce cancer risk in BRCA1/2 or Lynch syndrome carriers. Symptoms start abruptly, often within days, because estrogen and about half of circulating testosterone fall at once.

Treatment-induced POI

Ovarian failure after chemotherapy, pelvic radiation or ovarian surgery.

Most spontaneous POI has no identified cause. Known causes include genetic conditions such as Turner syndrome variants and the FMR1 (fragile X) premutation, and autoimmune disease, especially adrenal and thyroid autoimmunity. Finding a cause matters: it can affect your own health, your relatives’ testing and your fertility options.

The guiding principle differs from midlife menopause care. For a woman of 52, hormone therapy is a choice for symptom relief that weighs benefits and risks. For a woman of 35 without ovarian function, hormone therapy replaces hormones her body would normally still be making, and guidelines treat it as the default unless there is a specific contraindication. If you are in natural menopause around 50 instead, the menopause longevity protocol fits better.

02Why 12-minute care under-treats young women without ovarian function

In a short visit, POI and surgical menopause tend to be managed with rules written for women in their 50s and 60s. The result is predictable gaps:

1. Hormone therapy withheld out of WHI-era fear. The Women’s Health Initiative studied women with an average age of 63. Its risk findings do not apply to women under 45 replacing missing hormones, a point ACOG, ESHRE and The Menopause Society all make explicitly. Yet many young women are told hormones “cause breast cancer” and are offered nothing.
2. Under-dosing. Standard menopause doses, such as estradiol 25–50 mcg patches, are often too low to relieve symptoms or protect bone in a 30-year-old. Guidance for POI uses higher doses.
3. Stopping too early. The “lowest dose for the shortest time” message is applied, and therapy is stopped after a few years. For POI and early surgical menopause, the recommendation is to continue until at least about age 51.
4. No cause workup. Karyotype, FMR1 premutation testing and adrenal antibody screening are recommended for spontaneous POI but are frequently skipped. Missed adrenal autoimmunity can progress to adrenal insufficiency, which is dangerous.
5. Contraception and fertility confusion. Women with POI may still ovulate occasionally. Hormone therapy is not reliable contraception, and many are never told either fact.
6. Testosterone and mental health ignored. Low libido after oophorectomy is common and treatable; grief, anxiety and depression after an abrupt diagnosis are common and rarely addressed.

A longer integrative or menopause-specialist visit adds value by setting the right dose and duration, completing the workup and building a bone, heart and brain monitoring plan. Look for a clinician certified by The Menopause Society (MSCP) or with reproductive endocrinology experience.

03What untreated early estrogen loss does to brain, bone and heart

Most of the evidence comes from large observational cohorts, so it shows association rather than proof of cause, but the signals are consistent across studies.

• Bone. Estrogen loss speeds bone turnover. Women with POI have lower bone density and higher fracture risk, and the deficit is largest when estrogen replacement is delayed or inadequate. Bone density at diagnosis is a key baseline.
• Heart and blood vessels. Menopause before 45 is associated with higher rates of coronary heart disease and cardiovascular death. Observational data suggest hormone therapy started early reduces much of this excess risk.
• Brain. The Mayo Clinic Cohort Study of Oophorectomy and Aging found that women who had both ovaries removed before about age 45–46 and did not take estrogen until at least age 50 had higher risks of cognitive impairment, dementia and parkinsonism. Women who took estrogen did not show the same excess risk.
• Mortality. The same cohort and others link early bilateral oophorectomy without estrogen replacement to higher all-cause mortality.
• Sexual and urogenital health. Vaginal dryness, pain with sex and low libido are common, and genitourinary syndrome of menopause tends to progress without treatment.
• Mood and sleep. Abrupt estrogen loss is associated with depressive symptoms, anxiety and disrupted sleep.

These findings are the reason elective removal of healthy ovaries at hysterectomy is no longer routine for women at average risk, and why, when removal is necessary, hormone therapy is usually advised. For BRCA carriers, risk-reducing removal remains strongly recommended because ovarian cancer risk is high; hormone therapy afterward is generally considered appropriate for those without a personal history of breast cancer.

04The POI and surgical menopause panel: CPT codes, ICD-10 and targets

Spontaneous POI needs a diagnostic and cause workup; surgical menopause skips the cause tests but needs the same baseline for bone and heart. Common ICD-10 codes: E28.310 (symptomatic premature menopause), E28.39 (other primary ovarian failure, used for POI), E89.41 (symptomatic postprocedural ovarian failure), Z90.722 (acquired absence of both ovaries), Z15.01 and Z15.02 (genetic susceptibility to breast and ovarian cancer) and Z79.890 (hormone replacement therapy).

Table 1 · Ranges vary by lab and assay. Practitioner targets are clinical working goals, not guideline cut-offs; ESHRE does not require routine estradiol monitoring on HT. Codes must match documented findings.

Ovarian antibodies and broad “hormone mapping” panels are not recommended for diagnosis. To price the serum portion, use the lab cost builder.

05Hormone protocol: estradiol, progestogen and testosterone

The regimens below reflect ACOG Committee Opinion 698, the ESHRE POI guideline and The Menopause Society’s 2022 position statement. All named estradiol and progesterone products are FDA-approved and bioidentical.

Estradiol (the core)

• Transdermal estradiol patch, about 100 mcg a day — the most commonly cited POI dose; preferred route because it avoids first-pass liver metabolism and has lower clot risk than oral estrogen. Some women need 50–75 mcg, others more; dose is guided by symptoms and, if needed, a serum level.
• Oral estradiol, about 2 mg a day — an effective, inexpensive alternative when patches are not tolerated.
• Estradiol gel or spray — alternatives with dose flexibility.

Progestogen (if you have a uterus)

Estrogen alone thickens the uterine lining, so anyone with a uterus needs a progestogen. Options include oral micronized progesterone 200 mg for 12 days each month (cyclic, with a monthly bleed) or 100–200 mg daily (continuous), matched to the estradiol dose, or a levonorgestrel IUD. After hysterectomy, estrogen alone is used.

Combined hormonal contraception: an alternative

A combined pill gives contraception as well as estrogen. It is acceptable, but some studies show better bone and blood pressure outcomes with physiologic hormone therapy, and pills need continuous dosing to avoid symptomatic hormone-free weeks.

Testosterone

Removing the ovaries roughly halves circulating testosterone. The 2019 Global Consensus Position Statement supports testosterone only for hypoactive sexual desire disorder after menopause, including surgical menopause; evidence does not support it for bone, mood, energy or cognition. There is no FDA-approved testosterone product for women in the US, so clinicians prescribe an approved male gel off-label at about one-tenth of the male dose and keep levels in the premenopausal range. Testosterone is a Schedule III controlled substance. Compounded testosterone creams and pellets are not FDA-approved and can produce supraphysiologic levels; see pellets vs. transdermal patches and compounded vs. FDA-approved hormones.

When estrogen is not an option

After hormone-sensitive breast cancer, systemic estrogen is generally avoided. FDA-approved nonhormonal options for hot flashes include fezolinetant and elinzanetant (neurokinin receptor antagonists) and low-dose paroxetine; venlafaxine and gabapentin are used off-label. These relieve symptoms but do not protect bone, so bone-specific treatment may be needed. Low-dose vaginal estrogen is sometimes considered with oncology input.

06Bone, heart, brain and fertility support beyond hormones

Hormone therapy does the heavy lifting; the measures below add to it. Evidence strength is stated for each.

• Calcium, 1,000–1,200 mg a day, mostly from food — standard bone guidance; supplement only the shortfall. Strong evidence for adequacy, not for megadoses.
• Vitamin D, 800–2,000 IU a day if levels are low — supports bone with calcium; moderate evidence.
• Resistance and impact exercise, 2–3 sessions a week — improves bone density and muscle; moderate-to-strong evidence.
• Protein, about 1.0–1.2 g per kg of body weight a day — supports bone and muscle; moderate evidence.
• Creatine monohydrate, 3–5 g a day — with resistance training, may improve muscle strength in postmenopausal women; bone effects are inconsistent. Limited evidence.
• Omega-3 fats from fish — reasonable for heart health; supplement trials in women without heart disease are mixed. Limited evidence.
• No smoking, limited alcohol, and blood pressure and lipid control — strong evidence for heart and bone.
• Cognitive behavioural therapy and clinical hypnosis — evidence-based for hot flashes and sleep, especially when estrogen is not an option.

Fertility

Spontaneous pregnancy happens in about 5%–10% of women with POI, so use contraception if pregnancy is not wanted. If it is wanted, discuss timing with a reproductive endocrinologist early; IVF with donor eggs has high success rates, and egg or embryo freezing may be possible before planned surgery or cancer treatment.

Emotional support

A POI diagnosis or abrupt surgical menopause in your 20s or 30s can bring grief about fertility and identity. Counselling and peer support groups are part of good care, not an optional extra.

Track monitoring with a simple yearly plan: blood pressure, weight and symptom review every year; lipids and HbA1c every 1–3 years; thyroid antibodies yearly if positive; DEXA every 2–5 years depending on the first result.

07What the first 12 months cost

The first year carries the diagnostic workup; later years drop to medication, one or two visits and periodic labs. The genetic test line applies to spontaneous POI only. The insurance-hybrid column assumes in-network labs, DEXA and pharmacy, with clinician visits in-network or by out-of-network superbill.

Table 2 · Typical 2026 ranges and IntegrativeGyn.com estimates. FDA-approved patches and progesterone typically cost $15–$45 a month with insurance; commercial allowables run about $260–$485 for 99205. Counselling and fertility care are extra. Confirm current prices.

By contrast, a pellet program at $600–$1,200 per insertion, three to four times a year, costs $2,100–$4,200 in hormones alone and is rarely reimbursed. The BHRT 3-year cost comparator shows the gap over time, and the superbill and HSA/FSA guide covers reimbursement.

From year two, expect roughly $900–$3,000 a year cash, or $300–$1,200 with insurance: medication, one or two visits and targeted labs, plus a DEXA every few years. Because therapy is advised for a decade or more, the ongoing pharmacy route matters more than the first-year workup.

This page is educational and is not individual medical advice; discuss your own situation with a licensed clinician.